Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial
Bacterial infections are among the most life-threatening healthcare challenges, accounting for approximately 13.6% of global mortality and affecting 1 in 8 individuals worldwide ( Beyond their pathogenic roles, bacteria are integral to human health, especially in the gut, contributing to immune modulation and digestion ( The human microbiome, especially the gut microbiota, comprises numerous symbiotic bacterial species (e.g., Lactobacillus , Bacillus , Clostridium , Enterococcus , and Ruminococcus ) that collectively represent approximately 90% of the gut flora ( While antibiotics effectively eliminate harmful pathogens, their indiscriminate targeting also affects beneficial bacteria, reducing microbial diversity and increasing the likelihood of antibiotic resistance ( The decreasing efficacy of antibiotics and the limited availability of alternative treatments underscore the urgent need for new classes of antibacterial therapeutics
This blog is for informational purposes only and is not intended to substitute for medical advice
Immediately after the procedure, the treated area may appear minimally red in color
Here's a realistic timeline of what most patients experience during a BPC-157 protocol: Week 1-2 Early Response Reduced inflammation and pain at injection sites
